Intradialytic hypotension (IDH) is a common adverse event resulting in premature interruption of hemodialysis, and consequently, inadequate fluid and solute removal. IDH occurs in response to the reduction in blood volume during ultrafiltration and subsequent poor compensatory mechanisms due to abnormal cardiac function or autonomic or baroreceptor failure. Pediatric patients are inherently at risk for IDH due to the added difficulty of determining and attaining an accurate dry weight. While frequent blood pressure monitoring, dialysate sodium profiling, ultrafiltration-guided blood volume monitoring, dialysate cooling, hemodiafiltration, and intradialytic mannitol and midodrine have been used to prevent IDH, they have not been extensively studied in pediatric population. Lack of large-scale studies on IDH in children makes it difficult to develop evidence-based management guidelines. Here, we aim to review IDH preventative strategies in the pediatric population and outlay recommendations from the Pediatric Continuous Renal Replacement Therapy (PCRRT) Workgroup. Without strong evidence in the literature, our recommendations from the expert panel reflect expert opinion and serve as a valuable guide.
Introduction
D e s p i t e m e d i c a l a n d t e c h n o l o g i c a l a d v a n c e s , intradialytic hypotension (IDH) continues to be a common adverse occurrence in pediatric population resulting in premature interruption of hemodialysis, and consequently, inadequate fluid and solute removal [1] . The blood pressure (BP) in children is defined by using age-and gender-adjusted 5th percentile systolic blood pressure (SBP) measurements from the general population [2] , and IDH is defined as less than the 5th percentile of SBP measurements and is associated with clinical symptoms, such as abdominal pain, nausea, vomiting, muscle cramps, restlessness, light-headedness, syncope, and anxiety [3] . IDH occurs in response to the reduction in blood volume (BV) during ultrafiltration (UF) and subsequent poor compensatory mechanisms due to abnormal cardiac function (left ventricular dysfunction, chamber remodeling, congenital heart diseases, and arrhythmias) or autonomic or baroreceptor failure [1, 3] . To maintain volume status, the body shifts fluid from the interstitial space to the intravascular space and increases heart rate, contractility, and vascular tone. Plasma refilling, another essential factor in maintaining euvolemia, depends on oncotic, osmotic, and hydraulic gradients across vascular beds [3] . If UF rates surpass plasma refilling rates, intravascular volume falls and hypotension results. Hematocrit levels, tissue hydration and arterial vasoconstriction all promote plasma refilling rates. Alterations in these factors during dialysis decrease the plasma refilling rate, resulting in hypotension [3] . IDH must be distinguished from dialysis disequilibrium syndrome (DDS), which is due to neurological deterioration seen in patients receiving hemodialysis especially during or immediately following initial treatment, but can also occur in subsequent treatments [4] . DDS mimics symptoms of raised intracranial pressure or acute hyponatremia and includes restlessness, headache, confusion, and coma [4] . Other neurologic diagnoses must also be ruled out, as these symptoms are nonspecific [4] .
Pediatric patients are inherently at risk for IDH due to the added difficulty of determining and attaining an accurate dry weight [5] . While frequent BP monitoring, dialysate sodium profiling, UF-guided blood volume monitoring (BVM), dialysate cooling, and intradialytic mannitol and midodrine have been used to prevent IDH, they have not been extensively studied [1] .
To our knowledge, a consensus guideline of IDH preventative strategies in the pediatric population has not been conducted. Here, we aim to review these interventions and outlay recommendations from the Pediatric Continuous Renal Replacement Therapy (PCRRT) Workgroup.
Methods

Literature search
PubMed/Medline, Embase, and Cochrane Database were searched to include all publications involving IDH in the pediatric population using a specific search strategy (Appendix A and B). Returned citations were all reviewed individually for eligibility as per inclusion and exclusion criteria. Two reviewers independently assessed titles, abstracts, and full text articles for inclusion/exclusion criteria. A third independent reviewer conducted a similar assessment to overcome and settle any disagreements in data extraction. Inclusion c r i t e r i a w a s s t u d i e s i n v o l v i n g h e m o d i a l y s i s , hemodiafiltration (HDF) and hemofiltration (HF) in pediatric patients (age 0-18 years), reporting of hypotension during dialysis, pre-and post-dialysis BP measurement, difference between pre-and post-dialysis BP measurements, variable dialysate electrolyte concentration or dialysate temperature, and use of volume management/ UF strategies or pharmacological treatment for IDH. Studies were excluded if they involved adult population (> 18 years), or had no mention of hypotension during dialysis. Tables were created to reflect subject data, dialysis parameters, and outcomes of the included studies.
PCRRT Workgroup
The PCRRT Workgroup is composed of international pediatric nephrology experts representing the treatment of diverse pediatric populations. The experts from the PCRRT Workgroup and representatives from various international societies (Appendix C) participated in the consensus conference to discuss and provide recommendations on the management of IDH in the pediatric population. The consensus meeting took place at the 9th International Conference on Pediatric Continuous Renal Replacement Therapy, presented by the PCRRT Foundation on September 2, 2017 at Disney's Yacht & Beach Club Resorts, Lake Buena Vista, Orlando, FL. Rationale, background, objectives, and statistical methods of this initiative were supported by the PCRRT Workgroup. All the panel members were carefully selected by content expertise and potential conflicts of interests were disclosed. One panelist was an expert in epidemiology and guideline methodology. The chair of the PCRRT initiative was Dr. Timothy Bunchman (pediatric nephrologist, chair, and founder of the PCRRT at Richmond, VA), while co-chairs were Dr. Rupesh Raina (adult and pediatric nephrologist at Cleveland Clinic Akron General and Akron Children's hospital, Akron, OH) and Dr. Bradley Warady (pediatric nephrologist at Children's Mercy Hospital in Kansas City, MO).
Evaluation of recommendation strengths and determination of evidence level
The co-chairs completed the literature search, reviewed articles, extracted relevant data, and summarized findings, all of which were submitted to the workgroup for review and discussion. The workgroup was divided into subgroups, each of which reviewed an IDH preventative strategy in children and proposed recommendations. Voting by the entire workgroup was carried out to establish the strength of each of the recommendation statements using the modified Delphi method (Appendix D) [6] . Disagreements among panel members were resolved by quantifying votes using the RAND/UCLA Appropriateness Method and subsequently calculating a disagreement index [7] . The Grading of Recommendations, Assessments, Development, and Evaluation (GRADE) was used to establish an evidence level for clinical recommendations (Appendix D) [8] .
Results of literature search
The initial search returned 471 citations from all databases, with 366 citations remaining after removal of duplicates; only 17 (1 being a randomized study) studies met our inclusion criteria (Fig. 1) . Relevant data pertaining to hemodialysis parameters in 11 studies, patient characteristics, and outcomes were extracted and summarized in Tables 1 and 2 . Also, six studies involving HDF and HF were summarized in Table 3 . A total of 145 patients were included in 11 studies involving hemodialysis with ages ranging from 2.2 to 18 years. Hemodialysis indications included both acute kidney injury and chronic kidney diseases. To avoid heterogeneity of reported findings, we have excluded AKI patients from analysis. Hemodialysis duration ranged between 3 and 4 h with a frequency of 3-4 times/week. Both high flux and low flux dialysate membranes were used. Dialysate temperatures varied between 35°C to 37.5°C. Acute kidney injury etiologies (20 patients) were acute tubular necrosis, hemolytic uremic syndrome (HUS), tumor lysis syndrome, and drug toxicity, while chronic etiologies included focal segmental glomerulosclerosis, membranous glomerulonephritis, (n = 3) posterior urethral valves (n = 1) renal dysplasia (n = 2) cortical necrosis (n = 1) sickle cell nephropathy (n = 1) angiotensin converting enzyme inhibitor nephropathy (n = 1)
Not defined Biofeedback For patients < 35 kg, the event rate was significantly lower when NIVM was performed (no NIVM = 38/80, NIVM = 25/100, P = 0.01) Biofeedback technology was able to improve intradialytic symptoms. Additionally, without affecting dry weight estimations, NIVM assisted in lowering the frequency of dialysis-ultrafiltration associated morbidity in pediatric patients membranoproliferative glomerulonephritis, ANCA positive glomerulonephritis, polycystic kidney disease, renal dysplasia, and post-renal obstruction. Non-invasive BVM was the most commonly reported modality for prevention of IDH and was used in 36% (45/125) of patients. A total of 33 patients were included in four studies involving HDF for IDH prevention and ages ranged from 2.4 to 16.3 years. HDF duration ranged between 3 and 4 h/session and 3-6 times/week. Indications for HDF were malformative uropathy, Bardet Biedl syndrome, renal hypoplasia, corticoresistant nephrotic syndrome, nephronophthisis, Nail Patella syndrome, bilateral Wilms tumor, glomerular and hereditary diseases, HUS, Henoch-Schönlein syndrome, interstitial nephritis, cyclosporine A (CsA) toxicity after heart transplantation, Alport's syndrome, Wegener's granulomatosis, urethral valves, and autosomal recessive polycystic kidney disease (ARPKD). HF for IDH prevention was used in two studies comprising 78 subjects, but patient population was mixed involving both adults and children with ages ranging from 12 to 78 years.
Discussion and consensus panel recommendations
Preventative strategies
Modalities for IDH prevention included dialysate sodium profiling, BVM during UF, dialysate cooling, HDF, HF, and intradialytic administration of mannitol and midodrine.
Blood volume monitoring during ultrafiltration
A patient's dry weight refers to the lowest calculated weight a patient can reach following dialysis. If the weight falls below this value, the patient may experience symptomatic hypotension. Lack of standard dry weight calculations make accuracy difficult leading to miscalculations that can cause fluid overload or intravascular volume depletion [10] . Intradialytic BVM seeks to overcome this. BVM can be conducted through relative BVM or hematocrit monitoring [5, 10] . BVM technology includes a feedback loop based on Bfuzzy logic^con-trol systems, which allows the dialysis machine to monitor BV changes and adjust the UF rate and/or dialysate sodium concentration [23] . In these control systems, a rapid decrease in BV leads to a decrease in the UF rate and/or an increase in the dialysate sodium [23] . UF rate increases and dialysate sodium decreases when the BV is stable or decreases appropriately [23] . During hemodialysis sessions, the percentage change in BV can be continuously monitored through specialized devices that measure hemoglobin or hematocrit concentration. Newer dialysis machines have built-in BVM devices [10] . Innovative devices, such as Crit-Line® technology, measure SBP systolic blood pressure, UF ultrafiltration, NIVM non-invasive hematocrit monitoring, IME intradialytic morbid events, BVM blood volume monitoring, RBV relative blood volume, HD hemodialysis, BP blood pressure, BIA bioelectrical impedance, TBW total body water, DBP diastolic blood pressure hematocrit and oxygen saturation using photo optics that absorb or scatter light via erythrocytes [10] . The hematocrit measurement is inversely proportional to changes in BV allowing for real-time management of symptomatic hypotension [5] . This method assumes that the total red cell volume remains constant throughout the treatment [5] . Real-time intradialytic BVM using hematocrit measurements and a relative blood volume (RBV) slope helps achieve a balance between a patient's vascular refill and ultrafiltration (UF) rates [24] . Given the display features of the monitoring systems, intradialytic adjustments to the rate of fluid removal can be made; thereby potentially decreasing the frequency of IDH events [24] . Following hemodialysis initiation, the RBV value is routinely set to 100%, and adjustments are made according to this initial value [24] . The critical relative blood volume (RBVcrit) is defined as the RBV value that indicates increased frequency of hypotensive episodes [24] . The exact RBVcrit varies among patients and should be individually established per patient. If values approach the RBVcrit, the BVM device automatically reduces the UF rate [25] . However, it is important to note that the set value of 100% is not fixed; the fluid gain between dialysis treatments varies and is further influenced by inter-current illness and unique individual factors [23, 26] . Furthermore, as reported by Mitra et al., during UF, BV increases due to capillary vasoconstriction, resulting in vascular refill of the of the macrocirculation from the microcirculation (intravascular refill) [27] . These dynamic changes along with increase in central BV during UF underestimate the changes in systemic hematocrit and BV; the BVM concept assumes a constant circulating blood mass (volume) and component (hematocrit) [26, 27] .
The European Hemodialysis Guidelines for children recommend UF rates of 1.5 ± 0.5% of body weight per hour and a maximum UF volume of 5% of patient's dry weight per a 3-4 h conventional dialysis session without sodium and UF profiles or temperature control [28] . Hothi et al. compared a constant UF rate to varied UF patterns (decreasing step pattern, an alternating high/low UF rate and a decreasing linear pattern) in 10 patients. The UF profiles were no better than using constant UF rate [9] . In another study, Hothi et al. retrospectively reviewed records of 74 children and observed a correlation between RBV reduction and intradialytic adverse effects [11] . The gradient of the RBV curve during the first hour of dialysis treatment and the changes in intradialytic heart rate were the strongest predictors of intradialytic complications [11] . Fadel et al. noted that the assessment of dry weight based on non-invasive monitoring (NIVM) of hematocrit led to a significant reduction in the frequency of intradialytic-morbid events (light headedness, nausea, vomiting, or cramps) and associated hypotension [10] . In a retrospective study of pediatric intensive care unit (PICU) patients requiring hemodialysis for acute kidney injury, Merouani et al. found that BVM patients versus non-BVM patients had no difference in frequency of hypotension [5] . However, the mean UF volume was significantly higher in the BVM group compared to the controls (48 ± 27 vs. 33 ± 26 mL/kg; P < 0.001). They concluded that strict BVM allowed for an increased UF volume per session without affecting the incidence of hypotensive episodes [5] . Levtchenko et al. found that BV changes, displayed by Crit-Line® technology, were in fact related to changes in patient's weight during hemodialysis sessions [16] . Therefore, an approximation of dry weight in children using NIVM technology can aid in preventing intradialytic adverse events [16] .
Recommendations from the consensus panel for blood volume monitoring
All recommendations from the consensus conference including strengths and evidence level based on the methods described previously are summarized in Table 4 . Crit-Line® monitoring is recommended for acute and chronic pediatric hemodialysis treatments. The panel recognizes Crit-Line® monitoring may not be available worldwide. While level of evidence is low, a majority of panel members strongly recommended BVM in the management of IDH based on clinical experience. A physician order for use of the Crit-Line® monitor must be in place before hemodialysis initiation as the Crit-Line® blood chamber cannot be installed after the treatment has started. Use of the Crit-Line® monitor is conducted in the following manner.
Procedure
Begin by priming the circuit with the disposable blood chamber in place between the arterial header and the arterial line and attach the clip to blood chamber. Do not monitor UF profiling simultaneously with Crit-Line® monitoring. Set the hematocrit (Hct) limit at 2 Hct units above the starting Hct level. If the patient remains asymptomatic, the Hct level can be increased slowly 1 unit at a time during the session. Note, priming the dialysis circuit with blood will limit the usefulness of BVM.
Recommended BV change
Three to five percent per hour, up to 8% during the first hour, then 4% per hour in the subsequent hours with maximal total BV change of 16% at the end of the 4-h treatment.
Adjustments during treatment
UF goals and adjustment recommendations from the consensus panel are summarized in Table 4 . The Crit-Line® technology displays the slopes and profiles categorized as profiles A, B, or C (Fig. 2) .
& Profile A-Patient's plasma refill rate is occurring at the same or at an increased rate compared to the UF rate. 
3C
Step 
Refill assessment
At the end of treatment, if Hct decreases > 0.5% or BV increases > 1.5%, refill is present (patient not at dry weight). This assessment is based on clinical experience.
Normal oxygen saturation ranges
Arteriovenous fistula/arteriovenous graft (AVF/AVG) > 90%, central venous catheter (CVC) 60-80%.
Documentation
Use clinical markers (press arrow keys) to mark all events/ changes in treatment. Print the session document and place in patient's chart. If unable to print, chart the data (Hb, Hct, Sat, BV change) on the patient's run sheet at the start, hourly, and at the end of the session.
Dialysate sodium profiling
The majority of pediatric dialysis patients are fluid and salt overloaded, left ventricular mass index is increased in a substantial number; thus, the primary goal is to adequately balance fluid and salt homeostasis, which in many cases meant to remove salt especially in adolescent patients. In case IDH develops or the critical RBV is reached, prolongation of dialysis duration may be required rather than adding sodium to prevent IDH, which in the long run may increase thirst and create a vicious circle. Consistent automated BV monitoring almost inevitably results in prolongation of dialysis time.
Changes to dialysate sodium concentration should be made to maintain plasma osmolality with the goal to shift plasma water into the intracellular compartment [29] . Sodium profiling adjusts the sodium content of dialysate to directly influence the plasma sodium levels [29, 30] . Generally, the intracellular volume (ICV) constitutes 65% of total body water (TBW), whereas the extracellular volume (ECV) constitutes 35% [31] . Active transport and permeability of cell membranes equilibrate the electrolyte concentration between the intracellular and extracellular compartments [31] . Fluid shifts and changes in osmotic gradients between the intracellular and extracellular compartments contribute to IDH. By controlling the dialysate sodium concentration and water movement across the cell membrane, the number of hypotensive episodes can be reduced [32] . Although a complete review of the effects of dialysate sodium profiling is beyond the scope of this review, the authors would like to underscore its importance to IDH and the limitations of the available studies [33, 34] . Pediatric practice differs from adult practice in that children on dialysis more commonly have underlying sodium losing nephropathies [35] . Sodium tissue stores in these patients may differ from adults and children with glomerular diseases. As such, hemodynamic responses to the changes in dialysate sodium can differ among patients [33] . Unfortunately, this granularity of patient information is not provided in the published clinical studies and may account for some of the differences reported among studies. Nevertheless, patients undergoing hemodialysis with Fig. 2 Crit-Line® monitor display of slopes. Profile A-patient's plasma refill rate is occurring at the same or increased rate than the ultrafiltration. Profile B-no changes needed given the gradual slope and balance found between high ultrafiltration rate and avoidance of intradialytic symptoms.
Profile C-patient's display shows a steep slope representing a rapid decrease in blood volume and increases the risk of intradialytic symptoms. HCT, hematocrit; BV, blood volume; SAT, saturation a dialysate sodium concentration lower than their serum sodium are at higher risk for IDH and associated symptoms [36] . In contrast, higher dialysate to serum sodium concentration increases risk for a positive sodium and water balance leading to a higher risk for hypertension, a known risk factor for cardiovascular morbidity in patients with chronic kidney disease [36] . According to Tangvoraphonkchai and Davenport, the variable effects on BP control and adverse intradialytic events associated with lower dialysate sodium concentrations may be partially explained by patient selection and their differences in dietary sodium intake, urinary sodium losses, and sodium stores in the body [33] . Additionally, it is important to note that exact Bhigh^and Blow^dialysate sodium concentrations are not quantitatively defined; manufacturers allow variation in dialysate sodium concentration and in dialysis machine calibration by measuring dialysate conductivity (determined mainly by sodium and chloride) [33, 35, 36] . These factors further confound the prescribed versus delivered dialysate sodium to the patient.
Three dialysate sodium profiles exist in adults: increasing, alternating, and decreasing profiles (Table 5) . Although each profile has potential benefits for certain intradialytic symptoms, published work suggests that the decreasing sodium profile most effectively prevents or modifies IDH [31] . An increasing sodium profile, which is less commonly used, has reportedly reduced muscle cramps in patients, but may actually worsen symptomatic hypotension [32] . This profile conserves plasma volume near the end of treatment when UF remains high; however, this may worsen the decline in plasma osmolality during the first portion of treatment and increase the risk of IDH [29] . Thus, the increasing sodium profile is recommended for patients with muscle cramps and less susceptible to hypotension [31] . An alternating sodium profile using hypernatric and hyponatric dialysate introduces alternating fluid shifts across the cellular membrane to aid uremic toxin transport out of the cells via solvent drag. This profile may decrease the risk of disequilibrium syndrome, but there is no significant effect reported on hypotension [29] .
Decreasing sodium profiling can be done linearly, stepwise, or exponentially. The dialysate sodium concentration is highest at the start of treatment and gradually decreases until the end of the treatment [29] . At the start of hemodialysis, the solute removal rate is greatest; thus, a higher dialysate sodium concentration counteracts the rapid decline in the concentration of molecules like urea and minimizes the osmotic effect [29] . As the osmolality gradient decreases toward the end of dialysis, the low dialysate sodium promotes the diffusive clearance of the accumulated sodium load [29] . The decreasing profile also generally results in less interdialytic weight gain, which contributes to fewer hypotensive episodes [29] .
Sodium profiling to prevent IDH in pediatric populations has not been studied extensively. Hothi et al. compared linear versus step sodium profiling in ten patients with an initial dialysate sodium concentration of 148 mmol/L, with decreases to 138 mmol/L at the end of the dialysis session [9] . Linear sodium profiling achieves the final sodium concentration through a steady decline of the dialysate sodium concentration throughout the hemodialysis treatment. In step sodium profiling, the initial sodium concentration remains constant until 30 min prior to the end of the hemodialysis session, at which point the concentration of sodium is decreased to a final level of 138 mmol/L [9] . While this study did not show a significant difference between linear and step sodium ramping in preventing intradialytic symptoms, the linear profile did increase the odds of hypotensive episodes or premature discontinuation of treatment by 27% [9] . The authors concluded that the step ramping reduced the odds of IDH when compared to a linear profile [9] .
Recommendations from the consensus panel for dialysate sodium profiling
The consensus panel recommended decreasing sodium profiling to prevent or reduce IDH events when compared to increasing or alternative sodium profiling.
Step sodium profiling is better than linear sodium profiling in reduction of (Table 4) .
Cooling dialysate
Published literature regarding cooling dialysate for the management of IDH in pediatric populations is limited. Cooling dialysate to less than 36.5°C increases hemodynamic stability in adult studies [15] . However, the same concept cannot be applied to the pediatric population. While dialysate cooling is potentially beneficial, patient comfort may preclude its usefulness. A study involving 28 children by Hegazy et al. found that lowering the dialysate temperature to 35°C improved heart rate variability, tolerance to UF, and reduced IDH events [15] .
Consensus panel recommendations for cooling dialysate
The consensus panel discussed cooling dialysate recommendations to reduce/prevent IDH events in pediatric populations based on current evidence. Without a clear consensus, a majority of panel members consider use of cooling dialysate in cases of baseline temperature instability and in small children who may have disproportionate extracorporeal volume (with inherent cooling) compared to intravascular blood volume.
There is low level of evidence for lowering the dialysate temperature for the patient with repeated episodes of IDH (Table 4) .
Midodrine and mannitol
In addition to the aforementioned methods, prophylactic mannitol and rescue midodrine may be used in IDH management and are preferred over saline boluses [9] . Mannitol, an osmotically active solute, produces a more sustained oncotic effect than sodium and does not leak into the interstitium [13] . Midodrine prevents venous pooling and mediates central BP through its alpha-1 adrenergic agonist activity, which constricts both arterial and venous capacitance [13] . Hothi et al. studied six patients susceptible to intradialytic symptoms or IDH who received sequential dialysis (explained later) and prophylactic mannitol either at a dose of 1 g/kg in the first hour of first dialysis session of the week or 0.5 g/kg 2 times/week [13] . This study reviewed the value of sequential dialysis, intradialytic mannitol, and midodrine in these patients. In patients with IDH, 2.5 mg of oral midodrine was administered and repeated if IDH failed to improve within 30 min or if SBP fell below 75 mmHg with a maximum total cumulative dose of 7.5 mg per 3-h dialysis session [13] . Midodrine was not administered during last 30 min of a dialysis session regardless of BP changes [13] . Of the 399 sessions, intradialytic mannitol was administered in 57 (17%), sequential dialysis in 44 (11%), and midodrine in 20/144 (14%) dialysis sessions [13] . The combination of mannitol and sequential dialysis decreased the odds of IDH and intradialytic symptoms (abdominal pain, cramps, headaches, loss of consciousness, or change in behavior) [13] . Additionally, premature cessation of dialysis decreased by 50%. No intradialytic symptoms were seen with midodrine use [13] . In a separate study, , reported that while mannitol reduced the frequency of intradialytic symptoms, it did not prevent IDH [9] . Blowey et al. reported the case of an 18-year-old male with Bardet-Biedl syndrome who benefited from 10 mg of midodrine 45 min prior to the start of hemodialysis [12] . The patient continued midodrine for 4 months at which point midodrine was tapered and discontinued with no recurrence of IDH [12] .
Recommendations from the consensus panel regarding the use of midodrine and mannitol Due to lack of adequate clinical studies testing the efficacy of midodrine and mannitol in the management of IDH, the consensus panel members recommended the usage of these drugs could be appropriate in the face of hypo-osmolality or presence of inherent BP instability that is responsive to vasopressors. The level of evidence supporting its efficacy, however, is very low (Table 4) .
Procedure: If IDH is unresponsive to UF goal adjustments per Crit-Line® monitoring, the following order should be placed before starting dialysis: 
Bioelectrical impedance analysis
As noted previously, dry weight estimation of pediatric patients can be difficult as normal growth and weight gain need to be considered. Underestimating dry weight leads to hypovolemia and IDH symptoms, while overshooting dry weight results in fluid overload leading to increased risk for hypertension, pulmonary edema, congestive heart failure, and left ventricular hypertrophy [14] . Bioelectrical impedance analysis (BIA) non-invasively evaluates changes in TBW before, during, and after hemodialysis. BIA estimates body composition and fluid status to better calculate dry weight [14] . Brooks et al. used BIA variables and cardiovascular parameters (BP and heart rate) to predict relative changes in body fluid status and interdialytic weight gain [14] . This study suggested using BIA during dialysis to detect cardiovascular instability prior to development of IDH symptoms [14] . The consensus panel recommended against BIA in the management of IDH due to the scarcity of efficacious studies in pediatrics. Evidence for use is very low (Table 4) .
Hemodifiltration
Hemodifiltration is a technique that uses convective clearance in combination with diffusive clearance that is used in standard hemodialysis in order to provide more hemodynamic stability in addition to middle and small molecular clearance [19] . Compared to standard hemodialysis, HDF has been shown to improve hemodynamic stability and mortality rates in adult patients [1] . However, limited data is available in the literature to support this benefit in children. Thumfart et al. in their study involving seven children found that both nocturnal HDF and nocturnal hemodialysis reduced IDH events compared to conventional hemodialysis [19] . In another recent study by Zarauza-Santovena et al. involving seven pediatric patients, online-HDF reduced IDH events (0.21 episodes/patient/week vs 0.58; P = 0.028) compared to conventional HD [20] . Further, a study by Dheu et al. demonstrated a unique BVM curve that predicts the risk of hypotension during dialysis using online-HDF and BVM in 14 children [37] . In this study, normal BVM curve was observed in 91% of the dialysis sessions and described as initial rapid fall of BV < 8% in the first hour followed by progressive attainment of a plateau not less than a 12% RBV decrease, while the BVM curve that indicates the risk of IDH was observed in only 4% of the sessions and described as initial BV fall of > 8% without reaching a stable plateau [37] . In a pilot study involving five children, Fischbach et al. demonstrated the benefit of daily online-HDF (3 h, 6 times/week) compared to the standard online-HDF (4 h, 3 times/week) [21] . With the daily online-HDF, increased dialysis dose was achieved in addition to better tolerability and BP control without any complications [21] . Significant regression in left ventricular hypertrophy and improvement in left ventricular systolic function were also observed with the daily online-HDF [21] . Because of these beneficial effects of HDF, the majority of consensus panel members recommend using HDF as modality of choice in children with hemodynamic instability and frequent IDH episodes, although available scientific evidence is low (Table 4) .
Other modalities for IDH prevention
Other interventions in management of IDH include: UF profiling, sequential dialysis, biofeedback, quotidian hemodialysis, and UF rate adjustment based on body surface area. Limited or absent evidence for these techniques in children exists.
Ultrafiltration profiling
Ultrafiltration profiling adjusts the UF rate, thereby controlling the amount of fluid removed throughout the dialysis session. UF profiles, such as linear decrease, stepwise decrease, and alternating high/low UF profiling, have been tested in children. However, no significant benefit was observed with the use of UF profiling compared to constant UF rate [9] . The consensus panel recommended against this method in children (Table 4) .
Sequential dialysis
Sequential dialysis is hemodialysis following pure UF, which removes a large amount of isosmotic fluid [13] . Hothi et al. studied the effects of 30 min and 1 h sequential dialysis during 3-and 4-h hemodialysis sessions, respectively, in children and found significant reduction in intradialytic symptoms, but not in hypotensive episodes [13] . Expert panel members felt sequential dialysis may be appropriate in the setting of proportionally more fluid removal needs as opposed to solute clearance. However, evidence for its efficacy in IDH prevention is very low (Table 4) .
Biofeedback
Biofeedback controls UF rate and clearance based on negative feedback from the monitoring system [1] . In children, biofeedback systems function by UF algorithms that control UF rates and dialysate conductivity based on RBV changes to maintain RBV within the pre-set range during dialysis [18] . Using a constant dialysate sodium of 140 mmol/l, Jain et al. found that reductions of RBV < 8%/h in the first hour and < 4% thereafter are a safe approach to UF rate adjustment [18] . Alternatively, Hothi et al. utilized a range of dialysate sodium and UF rate adjustments and concluded that a cutoff threshold of 88% RBV in the first hour, 84% by the second hour, and 82% by the third hour were better predictors of intradialytic complications [11] . The expert panel felt that the evidence is low and recommended biofeedback technology use may be considered in the setting of a child or family that prefers a less invasive feedback approach. This approach requires consistent and continual interaction with family (Table 4) .
Quotidian hemodialysis
Quotidian hemodialysis is characterized by slow and gradual removal of fluid from the body, which consists of short, frequent dialysis sessions to maintain fluid balance and decrease intra and interdialytic adverse events [1] . Short daily dialysis involves 2-3 h dialysis sessions, 5 to 6 times per week, whereas frequent dialysis involves 4-5-h dialysis session every other day. While published data in children is limited, this method can decrease intradialytic adverse events (hypotension and postdialysis fatigue) [17] . While the consensus panel felt that the evidence is very low, this may be a reason why home hemodialysis is better tolerated than in-center hemodialysis (Table 4 ).
Body surface area based ultrafiltration rate adjustment
There is no published literature regarding body surface area based UF rate adjustment in children. Previous studies have discussed UF rates adjusted to body mass/weight. Daugirdas et al. found it advantageous to adjust UF rates to body surface area rather than body mass [38] . Due to the lack of clinical studies testing the efficacy of body surface area based UF rate adjustments in children, the consensus panel recommended against the usage of this method (Table 4) .
Hemofiltration
Hemofiltration is a technique that uses convective clearance and has been shown to be beneficial in preventing IDH events in very few studies that contained both adult and pediatric patients [22, 39] . Baldamus et al. involving six end stage renal disease patients (17-63 years age range) showed that HF decreased IDH events compared to hemodialysis [22] . In another study by Quellhorst et al. comprising 72 patients (12-78 years age range), the major reasons for switching from hemodialysis to HF were hypotension, hypertension, and/or frequent overhydration events, which indicates more hemodynamic stability with HF [39] . Due to scarcity of scientific evidence, consensus panel recommends against the use of HF technique for IDH prevention in children (Table 4) .
Limitations
Limitations of this review include a small number of studies, differences in illness severity, and varying methods among selected studies. Illness severity ranged from stable patients receiving outpatient hemodialysis to critically ill requiring hemodialysis in the intensive care unit. There were multiple methods used in each study, making comparison among them difficult. Furthermore, most of the studies were performed using Fresenius 2008 dialysis machines, which in view of the fact that many centers now use Fresenius 4008/5008 machines and that the pediatric version of the Fresenius 6008 machine is currently licensed sheds light on another difficulty of the reviewed scientific evidence. In addition, only one study used NxStage System One, and no studies tested other dialysis machines, such as Gambro, Nipro, Baxter, Dialife, and SWS hemodialysis machines, which adds to the difficulty of interpreting available scientific evidence. Future large-scale studies are necessary to further delineate the most effective methods for prevention of IDH.
Conclusions
Intradialytic hypotension remains a common complication of hemodialysis in children with a lack of effective therapeutic intervention. The associated lack of large-scale studies on IDH in the pediatric population makes it difficult to develop evidence-based management guidelines. However, our recommendations from the expert panel serve as a valuable guide. NIVM of hematocrit and lowering the dialysate temperature are, at present, the most effective clinical approaches for the management of IDH in children.
